Intrinsiqq
Kala Pharmaceuticals, Inc. logo

Kala Pharmaceuticals, Inc. Insider Trading

KALA

Compare
Last 12 months

No open-market buying or selling by insiders.

The last open-market buy by an executive or director was in Oct 2020.

Net open-market
$0
0 buys · 0 sales
Under a 10b5-1 plan
—
no sales
Insiders who bought / sold
0 / 0
executives and directors
Last open-market buy
Oct 2020
Oct 22, 2020

Get an email when KALA's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Oct 22, 2025 – Oct 23, 2025No plan
    Mary Reumuth
    Chief Financial Officer · sold 33,197 at avg $0.83
    28K
    53% of stake
  • Oct 23, 2025No plan
    Mark T Iwicki
    Director · sold 154,894 at $0.81
    125K
    60% of stake
  • Oct 22, 2025No plan
    Darius Kharabi
    Chief Business Officer · sold 20,806 at $0.83
    17K
    33% of stake
  • Oct 22, 2025No plan
    Todd Bazemore
    Director · sold 47,768 at $0.83
    40K
    57% of stake
  • Oct 22, 2025No plan
    Romulus K Brazzell
    See Remarks · sold 46,748 at $0.83
    39K
    57% of stake
  • Sep 30, 2025 – Oct 1, 2025No plan
    Julian Baker
    Other · sold 730,408 at avg $1.45
    $1.06M
    63% of stake
  • Jun 24, 202510b5-1 plan
    Darius Kharabi
    Chief Business Officer · sold 4,511 at $4.01
    18K
    6.7% of stake
  • Jun 24, 202510b5-1 plan
    Mary Reumuth
    Chief Financial Officer · sold 3,631 at $4.01
    15K
    5.5% of stake
  • Jun 24, 202510b5-1 plan
    Todd Bazemore
    See Remarks · sold 4,058 at $4.01
    16K
    4.6% of stake
  • Jun 24, 202510b5-1 plan
    Romulus K Brazzell
    See Remarks · sold 5,251 at $4.01
    21K
    6.0% of stake
  • Jun 24, 202510b5-1 plan
    Mark T Iwicki
    Director · sold 13,227 at $4.01
    53K
    4.9% of stake
  • Jun 3, 202510b5-1 plan
    Mark T Iwicki
    Director · sold 10,866 at $3.74
    41K
    3.9% of stake
  • Jun 3, 202510b5-1 plan
    Darius Kharabi
    Chief Business Officer · sold 730 at $3.74
    3K
    1.1% of stake
  • Jun 3, 202510b5-1 plan
    Mary Reumuth
    Chief Financial Officer · sold 2,850 at $3.74
    11K
    4.2% of stake
  • Jun 3, 202510b5-1 plan
    Todd Bazemore
    See Remarks · sold 3,390 at $3.74
    13K
    3.7% of stake
  • Jun 3, 202510b5-1 plan
    Romulus K Brazzell
    See Remarks · sold 3,687 at $3.74
    14K
    4.0% of stake
  • Jan 6, 202510b5-1 plan
    Darius Kharabi
    Chief Business Officer · sold 2,021 at $7.63
    15K
    2.9% of stake
  • Jan 6, 202510b5-1 plan
    Todd Bazemore
    See Remarks · sold 1,993 at $7.63
    15K
    100% of stake
  • Jan 6, 202510b5-1 plan
    Romulus K Brazzell
    See Remarks · sold 2,446 at $7.63
    19K
    2.6% of stake
  • Jan 6, 202510b5-1 plan
    Mark T Iwicki
    Chief Executive Officer · sold 5,779 at $7.63
    44K
    2.0% of stake
  • Jan 6, 202510b5-1 plan
    Mary Reumuth
    Chief Financial Officer · sold 1,706 at $7.63
    13K
    2.4% of stake
  • Dec 30, 2024
    Felix Baker
    Large holder · bought 310,559 at avg $6.44
    197K
    40% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch KALA, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with KALA

CompareIntrinsic value
PRPHProPhase Labs Inc.
$0.01-42.00%0
TRDAEntrada Therapeutics Inc.
$4.35-6.25%10
TXMDTherapeuticsMD, Inc.
$1.71-5.52%29
LPCNLipocine Inc.
$1.50+0.00%40
ATAIAtaiBeckley Inc.
$0.53-25.36%40
CNTBConnect Biopharma Holdings Ltd.
$0.59-6.05%10
MRKRMarker Therapeutics, Inc.
$1.11-15.91%25
PSTVPlus Therapeutics Inc
No recent price20

Spot a number that looks wrong? Check it in KALA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing KALA

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.